First introduced in the late 1990s for treatment of type 2 diabetes, thiazolidinediones are in the class of glitazones, an oral diabetes drug that decreases insulin resistance, while also treating hyperglycemia. The drug makes liver and skeletal muscle tissues more sensitive to the actions of insulin, increasing glucose absorption. The diabetes thiazolidinediones (pioglitazone and rosiglitazone) are sold as Actos and Avandia. They are also combined with other diabetes drugs, under the brand names of Duetact, Actoplus Met, and Avandamet. How these medicines work is not fully understood, but they aren’t able to produce more insulin. Instead, they help the body’s cells to use what insulin there is by lowering resistance. In the treatment of diabetes, thiazolidinediones should not be one’s first choice, as there can be serious side effects and a few of these drugs have been restricted by the U.S. Food and Drug Administration (FDA). They should only be …